{"id":"vinflunine-plus-capecitabine","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Mucositis"}]},"_chembl":{"chemblId":"CHEMBL2110725","moleculeType":"Small molecule","molecularWeight":"816.94"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Vinflunine's mechanism of action involves intercalating DNA, which prevents the replication and transcription of DNA. This leads to cell death, particularly in rapidly dividing cancer cells. Capecitabine, on the other hand, is converted into 5-fluorouracil, which inhibits thymidylate synthase, an enzyme necessary for DNA synthesis. This inhibition of DNA synthesis also leads to cell death.","oneSentence":"Vinflunine is a chemotherapeutic agent that intercalates DNA, thereby inhibiting DNA replication and transcription, while Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:34.803Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic transitional cell carcinoma of the urothelial tract"}]},"trialDetails":[{"nctId":"NCT01095003","phase":"PHASE3","title":"Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2009-05","conditions":"Breast Cancer","enrollment":770},{"nctId":"NCT01953003","phase":"PHASE3","title":"Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2013-09","conditions":"Malignant Neoplasm of Breast","enrollment":112},{"nctId":"NCT00450515","phase":"PHASE2","title":"Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2007-03","conditions":"Breast Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["JAVLOR","L00070 IN"],"phase":"phase_3","status":"active","brandName":"Vinflunine plus Capecitabine","genericName":"Vinflunine plus Capecitabine","companyName":"Pierre Fabre Medicament","companyId":"pierre-fabre-medicament","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vinflunine is a chemotherapeutic agent that intercalates DNA, thereby inhibiting DNA replication and transcription, while Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase. Used for Advanced or metastatic transitional cell carcinoma of the urothelial tract.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}